Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10822386 Insulin analogues with enhanced stability and reduced mitogenicity

Patent 10822386 was granted and assigned to Case Western Reserve University on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

November 3, 2020

0

Patent Application Number

155394500

Date Filed

December 24, 2015

0

Patent Citations

US Patent 10138284 Non-standard insulin analogues

US Patent 10703792 Insulin analogues with selective signaling properties and reduced mitogenicity

US Patent 10472406 Insulin analogues with selective signaling properties and reduced mitogenicity

0

Patent Citations Received

US Patent 11919935 Ultra-long acting insulin-Fc fusion proteins and methods of use

0

US Patent 11352407 Ultra-long acting insulin-Fc fusion proteins

US Patent 11359001 Insulin-Fc fusions and methods of use

US Patent 11555058 Cells engineered to express ultra-long acting insulin-Fc fusion proteins

US Patent 11261229 Ultra-long acting insulin-Fc fusion proteins and methods of use

US Patent 11267862 Ultra-long acting insulin-Fc fusion proteins and methods of use

US Patent 11667689 Insulin-Fc fusion proteins and methods of use to treat cancer

0

US Patent 11673934 Ultra-long acting insulin-Fc fusion proteins and methods of use

0

...

Patent Primary Examiner

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10822386 Insulin analogues with enhanced stability and reduced mitogenicity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool